BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

473 related articles for article (PubMed ID: 31526939)

  • 1. Anti-IgE treatment in allergic rhinitis.
    Bayar Muluk N; Bafaqeeh SA; Cingi C
    Int J Pediatr Otorhinolaryngol; 2019 Dec; 127():109674. PubMed ID: 31526939
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Etiopathogenesis and management of perennial allergic rhinitis: a state-of-the-art review.
    Bush RK
    Treat Respir Med; 2004; 3(1):45-57. PubMed ID: 15174893
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Anti-immunoglobulin E treatment with omalizumab in allergic diseases: an update on anti-inflammatory activity and clinical efficacy.
    Holgate ST; Djukanović R; Casale T; Bousquet J
    Clin Exp Allergy; 2005 Apr; 35(4):408-16. PubMed ID: 15836747
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Anti-IgE for the treatment of allergic rhinitis--and eventually nasal polyps?
    Verbruggen K; Van Cauwenberge P; Bachert C
    Int Arch Allergy Immunol; 2009; 148(2):87-98. PubMed ID: 18799888
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of omalizumab on symptoms of seasonal allergic rhinitis: a randomized controlled trial.
    Casale TB; Condemi J; LaForce C; Nayak A; Rowe M; Watrous M; McAlary M; Fowler-Taylor A; Racine A; Gupta N; Fick R; Della Cioppa G;
    JAMA; 2001 Dec; 286(23):2956-67. PubMed ID: 11743836
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The anti-inflammatory effects of omalizumab confirm the central role of IgE in allergic inflammation.
    Holgate S; Casale T; Wenzel S; Bousquet J; Deniz Y; Reisner C
    J Allergy Clin Immunol; 2005 Mar; 115(3):459-65. PubMed ID: 15753888
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Omalizumab for treatment of allergic rhinitis.
    Vashisht P; Casale T
    Expert Opin Biol Ther; 2013 Jun; 13(6):933-45. PubMed ID: 23621175
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The effect of omalizumab on nasal allergic inflammation.
    Plewako H; Arvidsson M; Petruson K; Oancea I; Holmberg K; Adelroth E; Gustafsson H; Sandström T; Rak S
    J Allergy Clin Immunol; 2002 Jul; 110(1):68-71. PubMed ID: 12110823
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Current Strategies to Inhibit High Affinity FcεRI-Mediated Signaling for the Treatment of Allergic Disease.
    Gomez G
    Front Immunol; 2019; 10():175. PubMed ID: 30792720
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Omalizumab rapidly decreases nasal allergic response and FcepsilonRI on basophils.
    Lin H; Boesel KM; Griffith DT; Prussin C; Foster B; Romero FA; Townley R; Casale TB
    J Allergy Clin Immunol; 2004 Feb; 113(2):297-302. PubMed ID: 14767445
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Omalizumab-induced reductions in mast cell Fce psilon RI expression and function.
    Beck LA; Marcotte GV; MacGlashan D; Togias A; Saini S
    J Allergy Clin Immunol; 2004 Sep; 114(3):527-30. PubMed ID: 15356552
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Omalizumab. A review of the new treatment of allergic asthma and seasonal allergic rhinitis.
    Félix Toledo R; Negro Alvarez JM; Miralles López JC
    Allergol Immunopathol (Madr); 2002; 30(2):94-9. PubMed ID: 11958741
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment of childhood asthma with anti-immunoglobulin E antibody (omalizumab).
    Milgrom H; Berger W; Nayak A; Gupta N; Pollard S; McAlary M; Taylor AF; Rohane P
    Pediatrics; 2001 Aug; 108(2):E36. PubMed ID: 11483846
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Anti-IgE--emerging opportunities for Omalizumab.
    Babu KS; Polosa R; Morjaria JB
    Expert Opin Biol Ther; 2013 May; 13(5):765-77. PubMed ID: 23517576
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A recombinant humanized anti-IgE monoclonal antibody (omalizumab) in the therapy of moderate-to-severe allergic asthma.
    D'Amato G; Piccolo A; Salzillo A; Noschese P; D'Amato M; Liccardi G
    Recent Pat Inflamm Allergy Drug Discov; 2007 Nov; 1(3):225-31. PubMed ID: 19075985
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Omalizumab: an effective anti-IgE treatment for allergic asthma and rhinitis.
    Casale TB;
    Drugs Today (Barc); 2004 Apr; 40(4):367-76. PubMed ID: 15190389
    [TBL] [Abstract][Full Text] [Related]  

  • 17. IgE-Related Chronic Diseases and Anti-IgE-Based Treatments.
    Navinés-Ferrer A; Serrano-Candelas E; Molina-Molina GJ; Martín M
    J Immunol Res; 2016; 2016():8163803. PubMed ID: 28097159
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Use of omalizumab in the treatment of food allergy and anaphylaxis.
    Lieberman JA; Chehade M
    Curr Allergy Asthma Rep; 2013 Feb; 13(1):78-84. PubMed ID: 23065311
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Biologics in allergic rhinitis.
    Bayar Muluk N; Cingi C
    Eur Rev Med Pharmacol Sci; 2023 Oct; 27(5 Suppl):43-52. PubMed ID: 37869947
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Omalizumab in children.
    Licari A; Marseglia A; Caimmi S; Castagnoli R; Foiadelli T; Barberi S; Marseglia GL
    Paediatr Drugs; 2014 Dec; 16(6):491-502. PubMed ID: 25404353
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.